Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
Summary · Access to medicines, prices and funding

Recent developments regarding multiple myeloma highlight advances in access to medications and funding. [Brazil] Tocantins has incorporated daratumumab into treatment, while [Portugal] the SNS has begun to fund new therapeutic combinations. The approval of medications such as Iberdoma [USA] and the expansion of the Melflufen monograph [USA] are also important milestones.

Made by MielomaAI On November 17, 2026, at 10:32, from recent news. May contain errors. View news →

Other myeloma medicines

Bispecific antibodies are given every week or every two weeks, for months, so the cost is counted per month. Public list prices (before discounts).

Teclistamab (Tecvayli)35.740 €Elranatamab (Elrexfio)37.550 €Talquetamab (Talvey)40.717 €

US monthly list price at launch (2022–2023), converted to euros.

MedicineUSA (list price)United Kingdom (per vial, excluding VAT)Portugal
Teclistamab (Tecvayli)
Johnson & Johnson
35.740 €/mês · 321.209 €–357.401 € por tratamento929,87 € (10 mg) · 4.741,82 € (90 mg)Confidential price
Elranatamab (Elrexfio)
Pfizer
37.550 €/mês · cerca de 298.588 € por tratamento2.946,26 € (44 mg) · 5.089,37 € (76 mg)Confidential price
Talquetamab (Talvey)
Johnson & Johnson
40.717 €/mês · 244.300 €–325.733 € por tratamento391,57 € (3 mg) · 5.220,73 € (40 mg)Confidential price
First line
combinations
Per year: VRd about 166.298 €; DRd about 345.691 €—In the SNS, at no cost to the patient

Sources: Source: Managed Healthcare Executive (Tecvayli) ↗ · Source: BioPharma Dive (Elrexfio) ↗ · Source: Fierce Pharma (Talvey) ↗ · Source: NICE TA1015 (teclistamab) ↗ · Source: NICE TA1023 (elranatamab) ↗ · Source: NICE TA1114 (talquetamab) ↗ · Source: Current Hematologic Malignancy Reports (1.ª linha) ↗

Amounts converted to euros: €1 = 1.1052 dollars and 6.1748 reais (European Central Bank reference rates of 13/11 and 09/11/2026) and 0.8336 pounds (market rate of 05/11/2026). The original amounts are in the sources. 2022–2023 prices may have risen since. Older medicines, such as lenalidomide, already have generics and cost much less.

Latest news on access, pricing and funding

All news → · Summaries created by MielomaAI; expand the article to read the original.